Reversing vemurafenib-resistance in primary melanoma cells by combined romidepsin and type I IFN treatment through blocking of tumorigenic signals and induction of immunogenic effects.
BRAFi
HDACi
IFN-α2b
MITF/AXL
melanoma
Journal
International journal of cancer
ISSN: 1097-0215
Titre abrégé: Int J Cancer
Pays: United States
ID NLM: 0042124
Informations de publication
Date de publication:
01 Sep 2023
01 Sep 2023
Historique:
revised:
28
03
2023
received:
22
12
2022
accepted:
04
05
2023
medline:
17
7
2023
pubmed:
9
6
2023
entrez:
9
6
2023
Statut:
ppublish
Résumé
BRAF
Substances chimiques
Vemurafenib
207SMY3FQT
romidepsin
CX3T89XQBK
Protein Kinase Inhibitors
0
Proto-Oncogene Proteins B-raf
EC 2.7.11.1
Interferon Type I
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1080-1095Subventions
Organisme : Associazione Italiana per la Ricerca sul Cancro
ID : IG 21614
Organisme : Current Research Funds
ID : OMM ISS 2018
Organisme : EU Erasmus+ ADVANCE Call 2019 Round 1 KA2
Informations de copyright
© 2023 The Authors. International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC.
Références
Guo W, Wang H, Li C. Signal pathways of melanoma and targeted therapy. Signal Transduct Target Ther. 2021;6:424.
Caksa S, Baqai U, Aplin AE. The future of targeted kinase inhibitors in melanoma. Pharmacol Ther. 2022;239:108200.
Hanly A, Gibson F, Nocco S, Rogers S, Wu M, Alani RM. Drugging the epigenome: overcoming resistance to targeted and immunotherapies in melanoma. JID Innov. 2022;2:100090.
Adams R, Coumbe JEM, Coumbe BGT, et al. BRAF inhibitors and their immunological effects in malignant melanoma. Expert Rev Clin Immunol. 2022;18:347-362.
Erin N, Grahovac J, Brozovic A, Efferth T. Tumor microenvironment and epithelial mesenchymal transition as targets to overcome tumor multidrug resistance. Drug Resist Updat. 2020;53:100715.
Arozarena I, Wellbrock C. Phenotype plasticity as enabler of melanoma progression and therapy resistance. Nat Rev Cancer. 2019;19:377-391.
Ostrowski SM, Fisher DE. Biology of melanoma. Hematol Oncol Clin North Am. 2021;35:29-56.
Oba J, Woodman SE. The genetic and epigenetic basis of distinct melanoma types. J Dermatol. 2021;48:925-939.
Emmons MF, Faiao-Flores F, Sharma R, et al. HDAC8 regulates a stress response pathway in melanoma to mediate escape from BRAF inhibitor therapy. Cancer Res. 2019;79:2947-2961.
Huijberts S, Wang L, de Oliveira RL, et al. Vorinostat in patients with resistant BRAF(V600E) mutated advanced melanoma: a proof of concept study. Future Oncol. 2020;16:619-629.
Wang L, Leite de Oliveira R, Huijberts S, et al. An acquired vulnerability of drug-resistant melanoma with therapeutic potential. Cell. 2018;173:1413-1425.
Gallagher SJ, Gunatilake D, Beaumont KA, et al. HDAC inhibitors restore BRAF-inhibitor sensitivity by altering PI3K and survival signalling in a subset of melanoma. Int J Cancer. 2018;142:1926-1937.
Que Y, Zhang XL, Liu ZX, et al. Frequent amplification of HDAC genes and efficacy of HDAC inhibitor chidamide and PD-1 blockade combination in soft tissue sarcoma. J Immunother Cancer. 2021;9:9.
Pojani E, Barlocco D. Romidepsin (FK228), a histone deacetylase inhibitor and its analogues in cancer chemotherapy. Curr Med Chem. 2021;28:1290-1303.
Paillas S, Then CK, Kilgas S, et al. The histone deacetylase inhibitor romidepsin spares normal tissues while acting as an effective radiosensitizer in bladder tumors in vivo. Int J Radiat Oncol Biol Phys. 2020;107:212-221.
Patel RP, Thomas JR, Curt KM, et al. Dual inhibition of histone deacetylases and the mechanistic target of rapamycin promotes apoptosis in cell line models of uveal melanoma. Invest Ophthalmol Vis Sci. 2021;62:16.
Shi Y, Fu Y, Zhang X, et al. Romidepsin (FK228) regulates the expression of the immune checkpoint ligand PD-L1 and suppresses cellular immune functions in colon cancer. Cancer Immunol Immunother. 2021;70:61-73.
Waldmann TA. Cytokines in cancer immunotherapy. Cold Spring Harb Perspect Biol. 2018;10:a028472.
Levati L, Alvino E, Pagani E, et al. Altered expression of selected microRNAs in melanoma: antiproliferative and proapoptotic activity of miRNA-155. Int J Oncol. 2009;35:393-400.
Lacal PM, Failla CM, Pagani E, et al. Human melanoma cells secrete and respond to placenta growth factor and vascular endothelial growth factor. J Invest Dermatol. 2000;115:1000-1007.
Fragale A, Romagnoli G, Licursi V, et al. Antitumor effects of epidrug/IFNalpha combination driven by modulated gene signatures in both colorectal cancer and dendritic cells. Cancer Immunol Res. 2017;5:604-616.
Motta M, Fasano G, Gredy S, et al. SPRED2 loss-of-function causes a recessive Noonan syndrome-like phenotype. Am J Hum Genet. 2021;108:2112-2129.
Motta M, Pannone L, Pantaleoni F, et al. Enhanced MAPK1 function causes a neurodevelopmental disorder within the RASopathy clinical spectrum. Am J Hum Genet. 2020;107:499-513.
Dobin A, Davis CA, Schlesinger F, et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics. 2013;29:15-21.
Anders S, Pyl PT, Huber W. HTSeq-a python framework to work with high-throughput sequencing data. Bioinformatics. 2015;31:166-169.
Huber W, Carey VJ, Gentleman R, et al. Orchestrating high-throughput genomic analysis with Bioconductor. Nat Methods. 2015;12:115-121.
Ashburner M, Ball CA, Blake JA, et al. Gene ontology: tool for the unification of biology. Nat Genet. 2000;25:25-29.
Buoncervello M, Romagnoli G, Buccarelli M, et al. IFN-alpha potentiates the direct and immune-mediated antitumor effects of epigenetic drugs on both metastatic and stem cells of colorectal cancer. Oncotarget. 2016;7:26361-26373.
Grasso CS, Tsoi J, Onyshchenko M, et al. Conserved interferon-gamma signaling drives clinical response to immune checkpoint blockade therapy in melanoma. Cancer Cell. 2020;38(500-15):e3.
Dankort D, Curley DP, Cartlidge RA, et al. Braf(V600E) cooperates with Pten loss to induce metastatic melanoma. Nat Genet. 2009;41:544-552.
Walia V, Prickett TD, Kim JS, et al. Mutational and functional analysis of the tumor-suppressor PTPRD in human melanoma. Hum Mutat. 2014;35:1301-1310.
Iqbal B, Masood A, Lone MM, Lone AR, Dar NA. Polymorphism of metastasis suppressor genes MKK4 and NME1 in Kashmiri patients with breast cancer. Breast J. 2016;22:673-677.
Xue Z, Vis DJ, Bruna A, et al. MAP3K1 and MAP2K4 mutations are associated with sensitivity to MEK inhibitors in multiple cancer models. Cell Res. 2018;28:719-729.
Baykara O, Tansarikaya M, Bulut P, Demirkaya A, Buyru N. CHD5 is a potential tumor suppressor in non small cell lung cancer (NSCLC). Gene. 2017;618:65-68.
Van Allen EM, Wagle N, Sucker A, et al. The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma. Cancer Discov. 2014;4:94-109.
Xu Z, Xu J, Sun S, et al. Mecheliolide elicits ROS-mediated ERS driven immunogenic cell death in hepatocellular carcinoma. Redox Biol. 2022;54:102351.
Pedri D, Karras P, Landeloos E, Marine JC, Rambow F. Epithelial-to-mesenchymal-like transition events in melanoma. FEBS J. 2022;289:1352-1368.
Sala M, Allain N, Moreau M, et al. Discoidin domain receptor 2 orchestrates melanoma resistance combining phenotype switching and proliferation. Oncogene. 2022;41:2571-2586.
Ludwig KF, Du W, Sorrelle NB, et al. Small-molecule inhibition of Axl targets tumor immune suppression and enhances chemotherapy in pancreatic cancer. Cancer Res. 2018;78:246-255.
Davis LE, Shalin SC, Tackett AJ. Current state of melanoma diagnosis and treatment. Cancer Biol Ther. 2019;20:1366-1379.
Diener J, Baggiolini A, Pernebrink M, et al. Epigenetic control of melanoma cell invasiveness by the stem cell factor SALL4. Nat Commun. 2021;12:5056.
Comito F, Pagani R, Grilli G, Sperandi F, Ardizzoni A, Melotti B. Emerging novel therapeutic approaches for treatment of advanced cutaneous melanoma. Cancers (Basel). 2022;14:14.
Verfaillie A, Imrichova H, Atak ZK, et al. Decoding the regulatory landscape of melanoma reveals TEADS as regulators of the invasive cell state. Nat Commun. 2015;6:6683.
Meel MH, de Gooijer MC, Metselaar DS, et al. Combined therapy of AXL and HDAC inhibition reverses mesenchymal transition in diffuse intrinsic pontine glioma. Clin Cancer Res. 2020;26:3319-3332.
Li J, Wang W, Zhang Y, et al. Epigenetic driver mutations in ARID1A shape cancer immune phenotype and immunotherapy. J Clin Invest. 2020;130:2712-2726.
Knox T, Sahakian E, Banik D, et al. Selective HDAC6 inhibitors improve anti-PD-1 immune checkpoint blockade therapy by decreasing the anti-inflammatory phenotype of macrophages and down-regulation of immunosuppressive proteins in tumor cells. Sci Rep. 2019;9:6136.
Matthews HK, Bertoli C, de Bruin RAM. Cell cycle control in cancer. Nat Rev Mol Cell Biol. 2022;23:74-88.
Awada G, Neyns B. Melanoma with genetic alterations beyond the BRAFV600 mutation: management and new insights. Curr Opin Oncol. 2022;34:115-122.
Shi CS, Kehrl JH. Bcl-2 regulates pyroptosis and necroptosis by targeting BH3-like domains in GSDMD and MLKL. Cell Death Discov. 2019;5:151-164.
Dixon KO, Tabaka M, Schramm MA, et al. TIM-3 restrains anti-tumour immunity by regulating inflammasome activation. Nature. 2021;595:101-106.